ArticleVirchows Archiv : an international journal of pathology2018
Size and heterologous elements predict metastases in malignant phyllodes tumours of the breast.
Article in Virchows Archiv : an international journal of pathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 47 citations in OpenAlex.
- Article
- Complete Remission of Metastatic Osteosarcoma From a Breast Malignant Phyllodes Tumor: A Case Report.Journal of breast cancer · 2025Article
- Malignant phyllodes tumours of the breast: the case for revising WHO's 'full house' diagnostic criteria.Histopathology · 2025Review
- Case Report: Recurrent phyllodes tumor of the breast with progressive malignant transformation.Frontiers in oncology · 2025Article
- Effects of radiotherapy in borderline and malignant phyllodes tumors after R0 resection: a propensity score analysis.Therapeutic advances in medical oncology · 2025Article
- Evaluation of the Clinicopathological Features Associated With Malignancy of Phyllodes Tumor of the Breast.Cureus · 2024Article
- Recurrent giant phyllodes tumor of the breast: a case report.AME case reports · 2024Article
- Prognostic factors of breast phyllodes tumors.Histology and histopathology · 2023Review
- Malignant phyllodes tumor of the breast with heterologous osteosarcoma and chondrosarcomatous differentiation: A rare case report with imaging findings.Radiology case reports · 2023Article
- The application of clinical variable-based nomogram in predicting overall survival in malignant phyllodes tumors of the breast.Frontiers in genetics · 2023Article
- Case report: Osteosarcomatous differentiation in the lung metastasis of a malignant phyllodes tumor.Frontiers in medicine · 2023Article
- Malignant phyllodes tumor of the breast with metastases to the lungs: A case report and literature review.Radiology case reports · 2022Article
- Therapeutic and immunomodulatory potential of pazopanib in malignant phyllodes tumor.NPJ breast cancer · 2022Article
- Fibroepithelial lesions revisited: implications for diagnosis and management.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2021Review
- Prognostic factors in phyllodes tumours of the breast: retrospective study on 166 consecutive cases.ESMO open · 2020Article
- A giant malignant phyllodes tumor of breast post mastectomy with metastasis to stomach manifesting as anemia: a case report and review of literature.BMC surgery · 2020Review
- Educational Case: Breast neoplasms: Phyllodes tumor of the breast.Academic pathologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Phyllodes tumours (PTs) of the breast are uncommon fibroepithelial neoplasms comprising 0.3-1.0% of all primary breast tumours. The majority of PTs are benign and generally well managed with surgery. However, malignant PTs, and occasionally borderline PTs, can behave in a clinically aggressive manner by metastasizing to distant organs. Although distant metastasis is rare, the prognosis of patients with metastasis is dismal as many are unresponsive to standard chemotherapy and the risk of death is high. In this study, we correlated clinicopathological parameters to survival outcomes in a cohort of patients diagnosed with malignant PTs in our institution. The study cohort comprised 83 cases of malignant PTs diagnosed at the Department of Anatomical Pathology, Singapore General Hospital from 1994 to 2015. Clinicopathological features and follow-up were obtained from hospital records. Metastasis-free survival (MFS) and overall survival (OS) were estimated with the Kaplan-Meier method and compared between groups using the log-rank test. Cox regression was carried out to identify factors predictive for metastasis. Mean and median age of patients was 48 years (range 21-71 years). Tumour size measured from 30 to 220 mm (mean 90 mm, median 77 mm). Follow-up data was available for 68 patients. Mean and median follow-up was 90 and 57 months, respectively, with a maximum of 291 months. Distant metastasis occurred in 16 out of 68 patients (23.5%). The most common site of metastasis was the lung. Malignant heterologous elements were observed in 16 (19.3%) cases. Individual clinicopathological parameters had no impact on outcome. On Kaplan-Meier analysis, women with large tumours and presence of malignant heterologous elements showed trends for poorer MFS (p = 0.217 and p = 0.566, respectively). However, the combination of large tumours (≥ 90 mm) containing malignant heterologous elements disclosed significantly worse MFS (p = 0.043) and a trend for poorer OS (p = 0.238). On multivariate analysis, large tumours harbouring malignant heterologous elements independently predicted metastasis (95% CI 1.041-12.517, HR 2.434, p = 0.049). Our study demonstrates that tumour size and presence of malignant heterologous elements predicted metastasis in malignant PTs. Further work needs to be done in determining if protein biomarkers and genomic aberrations are able to additionally refine metastatic risk and define therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.